In T2DM patients with mild to moderate CKD and HbA1cabove target despite triple therapy, QUADRUPLE THERAPY including metformin, SGLT2i, GLP1-RA and a fourth antidiabetic agent (AD) or insulin-based therapy is recommended to improve blood glucose control. The gene discussed is INS; the disease is chronic kidney disease.